T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results.
about
Adoptive T-Cell ImmunotherapyT lymphocytes targeting native receptorsTherapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinomaImmunotherapeutic Intervention against Sarcomas.Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.An overview of viral oncology in Italy - report from the Pavia meeting on solid tumors.Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.Combining drugs and biologics to treat nasopharyngeal cancer.Investigational drugs for nasopharyngeal carcinoma.Immunotherapy against cancer-related viruses.Generation of tumor-specific cytotoxic T-lymphocytes from the peripheral blood of colorectal cancer patients for adoptive T-cell transfer.Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine.Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.T cell therapy for nasopharyngeal carcinoma.Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment.Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma.
P2860
Q26782845-D5CBCA60-0F31-4011-8526-FF985D01CEEDQ26853345-F882B678-0A24-47CD-B7C5-54DCABC9B9B9Q27016002-AE9C126A-4010-4D4A-BCF3-0E34E643C76FQ34196481-022C6FF5-EE97-40BE-BEA3-2337C59F5BD3Q35507358-FB54CC50-1E1B-4548-9F4E-D0CCF340AF46Q36468756-A0B533F0-03CB-4CB5-A164-E587E31D2AE4Q37690437-F41D1E7D-6C4E-4F3A-B1F3-013040576C2BQ37690461-A9D29514-512A-4DE4-B07B-BDCD7B05CD11Q38690528-DC4839BF-C603-4C06-8724-2882C4D7E894Q38778924-C8F1C52F-7A3D-447F-A0CD-641FB7C57314Q38923514-DD7EA4C0-075C-4CDE-8AA1-96D9DF6F9D04Q39044990-4C038031-4C7F-4189-89F3-609D21D08CAEQ42145376-4444F5ED-8431-45A3-844E-0865EC132BC9Q42766336-D27FED4B-EDF7-447F-943E-555BABEFDE30Q49787173-961A8711-5011-4CA0-B718-0EE28ADB3A33Q51134076-8E877D35-83C5-4EFA-BB4F-D973B3302B9F
P2860
T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
T-cell therapy for EBV-associa ...... not improve clinical results.
@en
T-cell therapy for EBV-associa ...... not improve clinical results.
@nl
type
label
T-cell therapy for EBV-associa ...... not improve clinical results.
@en
T-cell therapy for EBV-associa ...... not improve clinical results.
@nl
prefLabel
T-cell therapy for EBV-associa ...... not improve clinical results.
@en
T-cell therapy for EBV-associa ...... not improve clinical results.
@nl
P2093
P2860
P50
P356
P1433
P1476
T-cell therapy for EBV-associa ...... s not improve clinical results
@en
P2093
F Locatelli
I Schiavetto
R Maccario
S Secondino
P2860
P304
P356
10.1093/ANNONC/MDR134
P50
P577
2011-05-17T00:00:00Z